martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 15, 2026

Warren Buffett once said this US investment was ‘terrible long-term.’ Now he has $381 billion of it. Should you get in?

View original at finance.yahoo.com
Warren Buffett once said this US investment was ‘terrible long-term.’ Now he has $381 billion of it. Should you get in? Paul Morigi / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • American business and a basket of stocks is virtually certain to be worth far more in the years ahead

    80% confidence
  • Risk comes from not knowing what you're doing

    80% confidence
  • Berkshire doesn't know how to use cash effectively and only swings at pitches they like

    80% confidence
  • As the world gets more sophisticated, complicated and intertwined, more can go wrong, and Berkshire aims to be prepared to act when that happens

    80% confidence
  • Berkshire's cash hoarding signals a 'risk-off' mindset that could concern investors about economy and markets

    80% confidence
  • Would invest $25 billion for 1% of all apartment houses in the country

    80% confidence
  • Berkshire's growing cash reserve raises questions about whether Buffett thinks stocks are overvalued, an economic downturn is coming, or is building cash for a big acquisition

    80% confidence
  • Doesn't have enough money in bank account to buy McDonald's in the morning despite $2.6 billion net worth

    80% confidence
  • 2026 will be the year 'when it gets real' for gold

    80% confidence
  • Cash equivalents are a terrible long-term asset that pays virtually nothing and is certain to depreciate in value

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com